Zheng, Fangchao
Du, Feng
Wang, Wenmiao
Wang, Yongsheng
Li, Ming
Zhao, Jiuda
Wang, Xue
Yue, Jian
Wang, Jiayu
Yang, Zixuan
Cai, Ruigang
Ma, Fei
Fan, Ying
Li, Qing
Zhang, Pin
Xu, Binghe
Yuan, Peng http://orcid.org/0000-0003-4627-8203
Clinical trials referenced in this document:
Documents that mention this clinical trial
Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up
https://doi.org/10.1007/s10549-021-06401-6
Funding for this research was provided by:
national key r&d program of china (2018YFC0115204)
csco pilot oncology research fund (Y-2019AZMS-0377)
capital health development research project (2018-2-4023)
non-profit central research institute fund of chinese academy of medical sciences clinical and translational medicine research fund (12019XK320071)
Article History
Received: 22 June 2021
Accepted: 26 September 2021
First Online: 14 October 2021
Declarations
:
: All authors declare that they have no conflict of interest.
: The study was carried out in accordance with the Declaration of Helsinki.
: Good Clinical Practice Guidelines and was also approved by the ethics committees of the participating hospitals.
: Not applicable.